Marco Taglietti, M.D.
President and Chief Executive Officer
Dr. Taglietti joined SCYNEXIS as President and Chief Executive Officer in April 2015 and has been a member of the board since November 2014. He became President of the Company in September 2015. He served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and as President of the Forest Research Institute until its acquisition by Actavis in 2014. Prior to joining Forest Laboratories in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc., a GSK company, for three years. He joined Stiefel Laboratories after 12 years at Schering-Plough Corporation, where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti currently serves on the Board of Directors of BioNJ, Inc. and Delcath (Nasdaq: DCTH). He received his medical degree and board certifications from the University of Pavia in Italy.
David Angulo, M.D.
Chief Medical Officer
Dr. Angulo joined SCYNEXIS as Chief Medical Officer in June 2015. He previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.
Chief Financial Officer
Mr. Francois joined SCYNEXIS as Chief Financial Officer in November 2015. He previously served as Co-founder and Chief Operating Officer of Topi, Inc., a technology startup, which he helped grow from inception to over 250 clients worldwide. Previously, Mr. Francois spent six years as a Director in the Equity Capital Markets Group at Lazard Ltd. (NYSE:LAZ) where he led capital raisings and advisory assignments for healthcare and biotechnology companies. He started his career at Cowen and Company (Nasdaq:COWN) in the Equity Capital Markets and Convertible Debt Groups. Mr. Francois holds a B.A. in Economics and Business Administration and a M.A. in Marketing from Pantheon-Sorbonne University.
Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017 after over a decade of addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development. Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.